Phase

Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards

Monday, September 27, 2021 - 4:00pm

Neurophth's proprietary manufacturing processes will take advantage of single-use equipment to aid in quick and effective product changeovers and equipment cleaning.

Key Points: 
  • Neurophth's proprietary manufacturing processes will take advantage of single-use equipment to aid in quick and effective product changeovers and equipment cleaning.
  • "Neurophth's own cGMP production facility is designed to enable us to reach manufacturing scales suitable for future commercial production and the facility is also co-located with our development laboratories," said Bin Li, Chairman and Founder at Neurophth.
  • We look forward to supporting Neurophth in the long run to strengthen its innovation and lead China's ocular gene therapy products and ultimately benefit patients around the world."
  • Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facilities.

REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call

Monday, September 27, 2021 - 12:05pm

REGENXBIO to host conference call and webcast to review the interim data from the AAVIATE trial on Friday, October 1, 2021, at 5:00 p.m.

Key Points: 
  • REGENXBIO to host conference call and webcast to review the interim data from the AAVIATE trial on Friday, October 1, 2021, at 5:00 p.m.
  • REGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented intwo oral presentations at the Retina Society 54th Annual Scientific Meeting taking place in Chicago, IL, from September 29 to October 2, 2021.
  • In connection with the presentation, REGENXBIO will host a webcast and conference call with accompanying slides on Friday, October 1, 2021, at 5:00 p.m.
  • SCS Microinjector is a trademark of Clearside Biomedical, Inc. All other trademarks referenced herein are registered trademarks of REGENXBIO.

Nanobiofab shapes medical training with AI-powered platform

Monday, September 27, 2021 - 12:50pm

Dr. Darrin Frye, Health Science Administrator and Medical Simulation Portfolio Manager at US Army Medical Research and Development Command (USAMRDC) Joint Program Committee -1 (JPC-1), is Nanobiofab's SBIR Technical Point of Contact, and works with Medical Simulation, AI, and nanotechnology.

Key Points: 
  • Dr. Darrin Frye, Health Science Administrator and Medical Simulation Portfolio Manager at US Army Medical Research and Development Command (USAMRDC) Joint Program Committee -1 (JPC-1), is Nanobiofab's SBIR Technical Point of Contact, and works with Medical Simulation, AI, and nanotechnology.
  • He states that this effort is a step in the continuing quest to improve medical simulation across healthcare training.
  • Throughout the test period, a variety of novel Nanobiofab smart sensors will be installed into the chest, belly, mouth, and extremities of high-fidelity medical mannequins.
  • By integrating our sensor array into medical mannequins, doctors and other medical professionals in training get that same feedback quickly.

Prime Mining Appoints New Board Member and Exploration Executive Q1 2022 Update on Exploration and Report to Shareholders

Monday, September 27, 2021 - 12:00pm

Prime is also pleased to provide an update on exploration and a report to shareholders concerning Q1 2022.

Key Points: 
  • Prime is also pleased to provide an update on exploration and a report to shareholders concerning Q1 2022.
  • On behalf of the board of directors and management, I welcome Edie to our Board and Scott as our key exploration executive.
  • Scott will lead our exploration program and team in our quest to continue the discovery process that will determine Los Reyes full potential.
  • The remaining 600,000 stock options will vest 1/3 after six months, 1/3 after twelve months, and 1/3 after eighteen months.

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

Monday, September 27, 2021 - 11:00am

The Benzinga Healthcare Small Cap Conference connects small cap companies, investors, and traders.

Key Points: 
  • The Benzinga Healthcare Small Cap Conference connects small cap companies, investors, and traders.
  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

Monday, September 27, 2021 - 11:50am

We are pleased to be collaborating with Georgetown University to work toward transforming the treatment landscape for these metastatic HR+/HER2- patients.

Key Points: 
  • We are pleased to be collaborating with Georgetown University to work toward transforming the treatment landscape for these metastatic HR+/HER2- patients.
  • Dosing the first patient is a critical milestone in advancing oral SM-88 as a potential treatment option prior to chemotherapy for this patient population.
  • This is a significant opportunity for TYME, and we look forward to providing updates as the OASIS trial progresses, concluded Cunningham.
  • The Company is enrolling a Phase II study evaluating SM-88 in breast cancer (HR+/HER2-) and continues enrollment of a Phase II study in high-risk metastatic sarcomas.

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

Thursday, September 23, 2021 - 11:00am

CEO Snehal Patel will make a virtual presentation on Wednesday, September 29, 2021 at 2:00 pm ET to conference attendees.

Key Points: 
  • CEO Snehal Patel will make a virtual presentation on Wednesday, September 29, 2021 at 2:00 pm ET to conference attendees.
  • The 6th Annual Cantor Global Healthcare Conference will include leading industry speakers and more than 300 presenting companies, one-on-one meetings, and panel discussions.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

North America miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User - ResearchAndMarkets.com

Wednesday, September 22, 2021 - 3:24pm

The "North America miRNA Sequencing and Assay Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America miRNA Sequencing and Assay Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • The North America miRNA sequencing and assay market, by product, is segmented into library preparation and consumables.
  • Based on technology, the North America miRNA sequencing and assay market is segmented into sequencing by synthesis, nanopore, and ion semiconductor sequencing.
  • Based on end user, the North America miRNA sequencing and assay market is segmented into research institute, academia, and CROs.

BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile

Wednesday, September 22, 2021 - 1:00pm

The trial tests BetterLifes proprietary inhaled interferon alpha-2b product, AP-003.

Key Points: 
  • The trial tests BetterLifes proprietary inhaled interferon alpha-2b product, AP-003.
  • The IFN-2b treatment arms will receive BetterLifes proprietary inhaled IFN-2b product, AP-003, administered via nebulizer, twice daily for 10 days.
  • The team, as well as the trial center, are the leaders in Chile in conducting COVID-19 trials.
  • The current IN2COVID trial in Chile was designed to test these.

SynAgile Corporation Announces Closing of Financing, Appointment of Mr. Michael McNamara to the Board of Directors, and Appointment of Dr. C. Warren Olanow as Chief Medical Officer

Wednesday, September 22, 2021 - 6:22am

The DopaFuse delivery system is the first non-invasive, continuous, levodopa-carbidopa delivery system.

Key Points: 
  • The DopaFuse delivery system is the first non-invasive, continuous, levodopa-carbidopa delivery system.
  • In conjunction with the financing, Mr. Michael McNamara has joined SynAgiles Board of Directors.
  • SynAgile also announces the appointment of Dr. C. Warren Olanow as SynAgiles Chief Medical Officer.
  • Dr. Olanow is a Co-Founder and Chief Executive Officer of Clintrex, a clinical research company.